Key Outcomes: Novel cell and gene approaches advanced, with Quell’s CAR‑Tregs entering P1/2 in RA/SSc and YolTech’s in vivo base‑editing therapy for AATD cleared for a global P2/3, signaling growing regulatory comfort with next‑gen modalities In metabolic and dermatology, AbbVie’s non‑incretin amylin analog ABBV‑295 showed meaningful P1 weight loss The immunology/rheum space saw expansion of […]

Key Outcomes: Novel immunology assets advancing, with JANX011 entering first-in-human testing and TREMFYA, Nemluvio showing durable 3‑year disease control without new safety issues Strong late-stage data in niche immune/neurology: remibrutinib hits P3 endpoint across CIndU subtypes and VYVGART improves ocular MG symptoms by week 4, supporting label-expansion filings Obesity and cardio‑metabolic focus intensifies: UBT251 achieves […]